JP2013504301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013504301A5 JP2013504301A5 JP2011545744A JP2011545744A JP2013504301A5 JP 2013504301 A5 JP2013504301 A5 JP 2013504301A5 JP 2011545744 A JP2011545744 A JP 2011545744A JP 2011545744 A JP2011545744 A JP 2011545744A JP 2013504301 A5 JP2013504301 A5 JP 2013504301A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- recombinant
- amino acids
- sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710092462 Alpha-hemolysin Proteins 0.000 claims description 32
- 241000191967 Staphylococcus aureus Species 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 230000027455 binding Effects 0.000 claims description 9
- 101000815632 Streptococcus suis (strain 05ZYH33) Rqc2 homolog RqcH Proteins 0.000 claims description 8
- 102000036072 fibronectin binding proteins Human genes 0.000 claims description 8
- 101710202686 Penicillin-sensitive transpeptidase Proteins 0.000 claims description 7
- 101710096749 Penicillin-binding protein 2A Proteins 0.000 claims description 6
- 241000191940 Staphylococcus Species 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229960005486 vaccine Drugs 0.000 claims description 5
- 108090000204 Dipeptidase 1 Proteins 0.000 claims description 4
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims description 4
- 206010040070 Septic Shock Diseases 0.000 claims description 4
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 4
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 4
- 102000006635 beta-lactamase Human genes 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 25
- 229920001184 polypeptide Polymers 0.000 claims 24
- 102000004196 processed proteins & peptides Human genes 0.000 claims 24
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 239000000232 Lipid Bilayer Substances 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000037430 deletion Effects 0.000 claims 6
- 238000012217 deletion Methods 0.000 claims 6
- 102000040430 polynucleotide Human genes 0.000 claims 6
- 108091033319 polynucleotide Proteins 0.000 claims 6
- 239000002157 polynucleotide Substances 0.000 claims 6
- 229940027941 immunoglobulin g Drugs 0.000 claims 5
- 230000037431 insertion Effects 0.000 claims 5
- 238000003780 insertion Methods 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 210000000170 cell membrane Anatomy 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000002949 hemolytic effect Effects 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 2
- 239000013554 lipid monolayer Substances 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 1
- 239000002052 molecular layer Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 101710198480 Clumping factor A Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09150888A EP2208787A1 (en) | 2009-01-19 | 2009-01-19 | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
| EP09150888.7 | 2009-01-19 | ||
| PCT/EP2010/050453 WO2010081875A1 (en) | 2009-01-19 | 2010-01-15 | A recombinant alpha-hemolysin polypeptide of staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013504301A JP2013504301A (ja) | 2013-02-07 |
| JP2013504301A5 true JP2013504301A5 (2) | 2013-03-21 |
| JP5781941B2 JP5781941B2 (ja) | 2015-09-24 |
Family
ID=40811673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011545744A Expired - Fee Related JP5781941B2 (ja) | 2009-01-19 | 2010-01-15 | ステムドメインにおける欠失および挿入された異種配列を有する黄色ブドウ球菌の組換えα溶血素ポリペプチド |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8545853B2 (2) |
| EP (2) | EP2208787A1 (2) |
| JP (1) | JP5781941B2 (2) |
| AU (1) | AU2010205645B2 (2) |
| CA (1) | CA2749862C (2) |
| ES (1) | ES2483720T3 (2) |
| WO (1) | WO2010081875A1 (2) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011010735A (es) | 2009-04-14 | 2012-01-25 | Novartis Ag | Composiciones para inmunizacion contra staphylococcus aureus. |
| AU2012214677B2 (en) | 2011-02-08 | 2016-11-10 | Abvacc, Inc. | Immunogenic composition comprising alpha-hemolysin oligopeptides |
| EP3470526A3 (en) * | 2011-02-08 | 2019-07-17 | Medimmune, LLC | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
| CN103648489A (zh) | 2011-05-11 | 2014-03-19 | 儿童医疗中心有限公司 | 多抗原提呈免疫原性组合物及其方法和用途 |
| WO2012178093A1 (en) | 2011-06-24 | 2012-12-27 | Electronic Biosciences Inc. | High contrast signal to noise ratio device components |
| CN102977214B (zh) * | 2012-09-29 | 2014-03-12 | 重庆原伦生物科技有限公司 | 用于耐甲氧西林金黄色葡萄球菌（mrsa）疫苗的重组蛋白hf2及制备方法和应用 |
| WO2014100481A2 (en) | 2012-12-20 | 2014-06-26 | Electornic Biosciences Inc. | Modified alpha hemolysin polypeptides and methods of use |
| JP6494527B2 (ja) | 2013-02-07 | 2019-04-03 | ザ チルドレンズ メディカル センター コーポレーション | 肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原 |
| BE1022857A1 (fr) * | 2014-03-26 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Immunisation contre staphylococcus aureus |
| CA2962241A1 (en) * | 2014-09-29 | 2016-04-07 | Fujifilm Corporation | Antibody-binding polypeptide, antibody-binding fusion polypeptide, and adsorption material |
| CN105641689B (zh) * | 2016-01-21 | 2024-09-10 | 浙江海隆生物科技股份有限公司 | 一种奶牛金黄色葡萄球菌β-溶血素亚单位疫苗的制备方法及应用 |
| US11414464B2 (en) | 2016-07-22 | 2022-08-16 | Evaxion Biotech A/S | Chimeric proteins for inducing immunity towards infection with S. aureus |
| AU2018243910B2 (en) | 2017-03-28 | 2025-04-10 | The Children's Medical Center Corporation | A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof |
| WO2018237221A1 (en) | 2017-06-23 | 2018-12-27 | Nosocomial Vaccine Corporation | IMMUNOGENIC COMPOSITIONS |
| TWI902669B (zh) | 2018-07-24 | 2025-11-01 | 美商麥迪紐有限責任公司 | 抗金黃色葡萄球菌凝集因子a(clfa)之抗體 |
| JP7535791B2 (ja) | 2018-09-12 | 2024-08-19 | ザ チルドレンズ メディカル センター コーポレーション | 肺炎球菌融合タンパク質ワクチン |
| IL281204B2 (en) | 2018-09-12 | 2025-07-01 | Affinivax Inc | Multivalent pneumococcal vaccines |
| CN113164602A (zh) | 2018-10-09 | 2021-07-23 | 免疫医疗有限责任公司 | 抗金黄色葡萄球菌抗体的组合 |
| IL326005A (en) | 2021-09-09 | 2026-03-01 | Affinivax Inc | Multivalent pneumococcal vaccines |
| WO2024168197A2 (en) * | 2023-02-08 | 2024-08-15 | The Regents Of The University Of California | Membrane translocation compositions and methods |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999005167A1 (en) * | 1997-07-25 | 1999-02-04 | University Of Massachusetts | Designed protein pores as components for biosensors |
| AU6033299A (en) | 1998-09-14 | 2000-04-03 | Nabi | Compositions of beta-glucans and specific igiv |
| US6849259B2 (en) | 2000-06-16 | 2005-02-01 | Symphogen A/S | Polyclonal antibody composition for treating allergy |
| CA2422867A1 (en) * | 2000-09-15 | 2002-04-25 | University Of Connecticut Health Center | Improved formulations using heat shock/stress protein-peptide complexes |
| GB0107661D0 (en) * | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| EP1524991A1 (en) * | 2002-08-02 | 2005-04-27 | GlaxoSmithKline Biologicals S.A. | Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria |
| KR20070058631A (ko) * | 2004-09-22 | 2007-06-08 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
| EP2043690A1 (en) | 2006-06-12 | 2009-04-08 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
-
2009
- 2009-01-19 EP EP09150888A patent/EP2208787A1/en not_active Withdrawn
-
2010
- 2010-01-15 CA CA2749862A patent/CA2749862C/en not_active Expired - Fee Related
- 2010-01-15 ES ES10700742.9T patent/ES2483720T3/es active Active
- 2010-01-15 WO PCT/EP2010/050453 patent/WO2010081875A1/en not_active Ceased
- 2010-01-15 US US13/143,795 patent/US8545853B2/en not_active Expired - Fee Related
- 2010-01-15 EP EP10700742.9A patent/EP2382316B1/en not_active Not-in-force
- 2010-01-15 JP JP2011545744A patent/JP5781941B2/ja not_active Expired - Fee Related
- 2010-01-15 AU AU2010205645A patent/AU2010205645B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013504301A5 (2) | ||
| Ord et al. | A malaria vaccine candidate based on an epitope of the Plasmodium falciparum RH5 protein | |
| JP5781941B2 (ja) | ステムドメインにおける欠失および挿入された異種配列を有する黄色ブドウ球菌の組換えα溶血素ポリペプチド | |
| Mann et al. | Broadly protective protein-based pneumococcal vaccine composed of pneumolysin toxoid–CbpA peptide recombinant fusion protein | |
| CN103890174B (zh) | IgG结合性肽及利用其检测和纯化IgG的方法 | |
| CN102892885B (zh) | IgA结合性肽以及利用其的IgA的纯化 | |
| JP2014506132A5 (2) | ||
| Yi et al. | Protection of Nile tilapia (Oreochromis niloticus L.) against Streptococcus agalactiae following immunization with recombinant FbsA and α-enolase | |
| May et al. | Identification of fibronectin-binding proteins in Mycoplasma gallisepticum strain R | |
| JP2011523550A5 (2) | ||
| JP2018517708A (ja) | 抗ブドウ球菌生物学的薬剤のための組成物及び方法 | |
| CN104844712B (zh) | 肺炎链球菌蛋白抗原及其制备方法和应用 | |
| JP2008530037A (ja) | 表面に位置したＳｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅのポリペプチド | |
| Zhang et al. | Prevalent distribution and conservation of Streptococcus suis Lmb protein and its protective capacity against the Chinese highly virulent strain infection | |
| JP2016501266A5 (2) | ||
| Khan et al. | IgY‐binding peptide screened from a random peptide library as a ligand for IgY purification | |
| JP7643730B2 (ja) | ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ）プロテインＡ（ＳｐＡ）変種を含む方法および組成物 | |
| Smidt et al. | Comprehensive antigen screening identifies Moraxella catarrhalis proteins that induce protection in a mouse pulmonary clearance model | |
| Reese et al. | Purification of animal immunoglobulin G (IgG) using peptoid affinity ligands | |
| JP7117244B2 (ja) | 黄色ブドウ球菌疾患の間にコアグラーゼ活性を中和する抗体に関連した組成物および方法 | |
| Rudolph et al. | Structural elucidation of a protective B cell epitope on outer surface protein C (OspC) of the Lyme disease spirochete, Borreliella burgdorferi | |
| JP2019514343A5 (2) | ||
| Walczak et al. | Method for generation of peptide‐specific igy antibodies directed to Staphylococcus aureus extracellular fibrinogen binding protein epitope | |
| Engmark et al. | High-density peptide microarray exploration of the antibody response in a rabbit immunized with a neurotoxic venom fraction | |
| Schennings et al. | Protective immunization against S taphylococcus aureus infection in a novel experimental wound model in mice |